Method of treatment of glaucoma optic neuropathy
SUBSTANCE: Invention relates to ophthalmology, and can be used for treatment of glaucoma optic neuropathy. Dibicor in dose 0.5g two times a day during 1 month, then cortexin and retinalamin in dose 10 mg intramuscular every second day during 20 days are prescribed. Method allows to increase electrophysiological activity of visual analyser in patients with primary open-angular glaucoma due to pathogenically grounded successive application of said medications, on the first stage of treatment intracellular exchange in ganglionar cells of retina improves, then synaptic lesions and transmission of nerve impulse from retina to cortical centre of visual analyser are activated.
EFFECT: increase of electrophysiological activity of visual analyser in patients with primary open-angular glaucoma.
1 tbl, 1 ex
The invention relates to medicine, namely to ophthalmology, and can be used for the treatment of glaucomatous optic neuropathy.
Primary open-angle glaucoma (POAG) is the most common eye disorders among the adult population and is the 1st rank among causes of disability in many regions of Russia (Libman E.S., Shakhova E.V. Blindness and visual disability in the population of Russia. // Proc. Dokl. VIII Congress of ophthalmologists of Russia. - M., 2005. - p.78-79).
For patients with POAG is characterized by the progression of the pathology of the optic nerve in optic neuropathy, despite the normalization of the IOP local antihypertensive agents or microsurgical or laser treatment.
To improve visual function in the pathology of the visual analyzer of different Genesis in recent years, the use of complex peptide drugs (Cortexin, ritalin, the medication).
There is a method of treatment of amblyopia (RF Patent 2205042, 2003, bull. Fig. No. 15), which provides for the appointment of Cortexin in the form of endonasal electrophoresis in combination with magneto and electrostimulated optic nerve.
The disadvantage of this method is its low efficiency in the treatment of patients with POAG, which has a complex pathogenesis with the main link in the form of reduced antioxidant is the first system of the body (Smith E.A., Alekseev, V.N. and other Pathogenetic aspects of treatment of primary otkrovennoi glaucoma. - M., 2001. - p.42-43).
There is a method of treatment of amblyopia in children with delayed cognitive development (RF Patent 22726442, 2006, bull. Fig. No. 9), the essence of which consists in the introduction of Cortexin intramuscularly, a course of 10 treatments with simultaneous application of neuroprotective drug - Semax in the form of intranasal installations.
The disadvantage of this method is incomplete, the validity of his appointment with glaucoma, as the basis for the development of glaucomatous optic neuropathy lies initial loss of ganglion cells of the retina with subsequent defeat them appendages of the optic nerve fibers, and amblyopia decrease in visual acuity observed without organic lesions of the visual and nervous system, as it was shown by Prof. Escavation (Avetisov AS Divinatory amblyopia and its treatment. - M.: Medicine, 1968).
Known method for improving the visual function of the eye by acting on neuroreceptors apparatus of the retina drug ritalin (RF Patent 2073518, 1997, bull. Fig. No. 1 "Means that restores the function of the retina).
The disadvantage of this method is its local impact on the metabolism of the cells of the retina, which limits its effectiveness in the treatment of glaucomatous optic neuropathy.
The known is the way, providing simultaneous use of complexes of peptide drugs: ritilin - parabulbarno and Cortexin and epithalamin intramuscularly (RF Patent "Method of treatment of diabetic retinopathy" No. 2157154, 2000, bull. Fig. "31).
The disadvantage of this method is the use of the preparation epithalamin, which (according to the Patent of the Russian Federation 944191, 1980, bull. Fig. No. 19, "Method of obtaining compounds having antitumor action) increases the sensitivity of the hypothalamus to endogenous influences that may contribute to increased intraocular pressure and reduction of visual functions in patients with glaucoma.
The closest technical solution to the claimed method and taken for the prototype is a Method of treating visual analyzer (RF Patent 2206299, 2003, bull. Fig. No. 18). The method consists in the use of ritilin, which is injected through the irrigation catheter into the retro-bulbar space in 0.5 ml of 5 times per day after 3 hours, additional intramuscularly Cortexin in 1.0 ml of 1 times a day, and spend svetonepronitsaemostyu of the visual analyzer in combination with the training of the accommodation on the computer one session a day for 10 days.
The disadvantage of this method is its invasiveness, potential for the development of vascular or inflammatory Oslon the deposits of the orbit. The disadvantages of this method include the need for treatment in the eye hospital, which limits its use compared to the ambulatory nature of the treatment.
The objective of the invention: improved efficiency and availability medicalmassage treatment of glaucomatous optic neuropathy.
The task is achieved by the fact that the first POAG patients with normalized intraocular pressure get Nik inside of 0.5 g per day for 1 month, then Cortexin and Retinalamin 10 mg intramuscularly every other day for 20 days.
In this way treated 23 patients (46 eyes) aged 54-65 years - the Core group with POAG advanced stage, with normalized intraocular pressure with 2-fold instillation of 0.5% solution of timolol.
As a comparison deals with the results of treatment in 24 patients (48 eyes) of similar age and condition of POAG who have an overall treatment included Cortexin 10 mg intramuscularly for 10 days in combination with a nootropic drugs (cinnarizin or piracetam) 1 tab. 3 times a day for 1 month. - Control group.
These regimens patients of the Main group repeated 2 times per year, patients in the Control group were repeated 3 times per year.
Treatment efficacy was analyzed after 1 year in all patients with POAG.
Given the importance of the process Perek the red lipid oxidation in the metabolism of structures of the visual analyzer, we have included a list of criteria for the effectiveness of the rate of activity of SOD (superoxide dismutase enzyme antioxidant system) along with the indicators of the air and fields of view that reflect the functional activity of the visual analyzer. The analyzed results are presented in the table.
|Indicators||The main group||The control group|
|The source data||After 1 month of treatment||The source data||After 1 month of treatment|
|Field of view||465,2°±3,3||476,1°±2,4||474°±3,7||464,1°±2,8|
|P, % change||P<0,05||↑ 0.2%||P>0,05||↓ 2%|
|The threshold EB retinal µa||122±5,6||to 114.7±3,9||to 121.6±4,8||134,0±4,1|
|% change P||P<0,05||↓ 6%||P>0,05||↑ 10%|
|The threshold E is maturing. nerve Hz||32,2±1,1||33,5±2,0||32,4±1,6||31,3±1,8|
|% change, P||P>0,05||↑ 4%||P>0,05||↓ 3.4%|
|SOD (superoxide dismutase), u/askt/mn ER||151,1±5,2||of 180.5±5,3||156,3± and 4.9||168, 8mm±4,7|
|% change, P||P<0,05||↑ 19%||P>0,05||↑ 8%|
|The multiplicity of repeated courses||2 times per year||3 times a year|
These tables show the advantage of the proposed method, which allows significantly (P<0,05) to improve visual function (electrophysiological indices, field of view) in patients with glaucoma, while patients in the Control group, a slight deterioration of these indicators, though the differences are not statistically significant (P>0,05)
The important thing is improving antioxidant defenses patients with glaucoma after proposed method of treatment, as evidenced by a significant (P<0,05) increase of SOD activity by 19% compared with the original data. In the Control group, although this figure increased by 8%, but the differences are not statistically significant (P>0,05).
The advantages of the proposed method can be attributed to a lower multiplicity of courses of treatment compared with the Control group, and for the efficiency of the treatment at home.
The positive results of the treatment by the proposed method confirm its pathological focus, because the consistent use of these drugs allows to correct major violations in the body and the visual analyzer patients with glaucoma.
Nik: the active drug substance is taurine, which is a natural product of the metabolism of sulfur-containing amino acids (cysteine, group probably facilitates methionine). The drug has a positive effect on the composition of the phospholipids of cell membranes, normalizes intracellular metabolism, improves the transport of calcium ions and potassium (Reference Vidal, 2005, s).
If we consider that the safety of the phospholipid membranes of neuroreceptors and ion transport provide the functional activity of the retina, the reception and processing of visual information (Samsonova A. M., Volkov V.V. Functional methods of research in ophthalmology. - M., 2004), this fact justifies the inclusion of the drug Nik treatment under the proposed method.
The inclusion of Retinalamin enhances electrogenic retina because of its stimulating effect on the photoreceptors and cellular elements of the retina, including the ganglion cells are the first to die in glaucoma.
Is valid and the inclusion of Cortexin, which which regulates the processes of lipid peroxidation in brain cells (Litvinenko N.A. Lipid peroxidation, physiological antioxidant system under various extreme conditions and their regulation of the polypeptide Cortexin: author. dis... Kida. the honey. Sciences. - Kharkov, 1992).
Thus, the proposed method for the treatment of glaucomatous optic neuropathy is pathogenetically justified, effective and has a number of advantages compared to traditional medicamentosas treatment of patients with glaucoma.
As confirmation of the results obtained here are clinical example.
B-Naya I. 56 years. Diagnosis: POAG, advanced stage with normalized intraocular pressure of both eyes. Visual acuity:
OD=0,7 Sph(+) 1,0D=1,0 IOP=18,0 mm Hg
OS=0,6 Sph(+) 1,0D=1,0 IOP=19,0 mm Hg
The fundus of both eyes: DOP b/pink; e/D=0,6-0,5; artery evenly narrowed.
B-Naya buries of 0.5% p-p of timolol in both eyes. During the year 3 times received registrationthe treatment (piracetam or cinnarizin 1 table 3 times a day for 1 month and additionally Cortexin 10 mg/m No. 10).
After 1 year u b-s And. worsened field of view a total of 8 meridians with 470° to 414°, i.e. by 12% in my right eye, and with 475° to 367, i.e. by 15% over his left eye.
The threshold E optic nerve decreased from 33 Hz to 32 Hz in both eyes. The threshold EB retina remained 120 µa in my right eye and 124 µa over his left eye. B-Neu were treated according to the SNO invention, Nik 0.5 g reg. OS 2 times per day for 1 month, then Cortexin and Retinalamin 10 mg/m every other day for 20 days. The treatment was repeated 2 times per year. A year later the visual acuity of both eyes is 1.0. The picture of the fundus has not changed. Field of view a total of 8 meridians increased to 485° on his right eye and 480° on the left, respectively, 10.3% above the original value on the right eye and by 10.2% in the left eye. The threshold E in both eyes was 34 Hz, i.e. increased by 10.6%, the threshold EB retina decreased in both eyes to 110 μa, which is 11.3% higher than the original data. Treatment was performed on an outpatient basis.
After 6 months treatment effect remained.
Comparative characteristics of the patients with glaucoma and Control groups.
A method for the treatment of glaucomatous optic neuropathy, including the introduction of complexes of peptide drugs, characterized in that the first patients receive Nik 0.5 g 2 times a day for 1 month, then Cortexin and Retinalamin 10 mg intramuscularly every other day for 20 days.
SUBSTANCE: method involves introducing anecortavi acetas at a dose of 3-15 mg in posterior juxtascleral injection or injection into vitreous body or as implant.
EFFECT: enhanced effectiveness of treatment.
18 cl, 5 dwg, 4 tbl
FIELD: organic chemistry, medicine, biochemistry pharmacy.
SUBSTANCE: invention relates to using the known 2-phenyl-substituted imidazotriazinone of the formula (I): (vardenafil) possessing improved properties as compared with other known inhibitors of phosphodiesterase-5 (PDE-5), such as sildenafil and tadalafil. Proposed compound is used for preparing drugs used in treatment of cardiac insufficiency.
EFFECT: valuable medicinal and biochemical properties of compound.
FIELD: medicine, ophthalmology, chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to design of ophthalmological agents of broad spectrum based on vegetable components, vitamins and trace elements. Agent for treatment of eye diseases comprises bilberry berries of sublimation drying, dihydroquercetin, beta-carotene, selexen, lutein, vitamins B1, B2, B6, B12 and zinc. Agent shows the effect of broad spectrum and possesses regenerating, tonic and regenerative effect being without irritating, allergizing, inflammatory and other undesirable effects, and excluding mechanical contact with eye surface.
EFFECT: valuable medicinal properties of agent.
SUBSTANCE: method involves carrying out tonometry, patient examination in slit lamp light, determining filtration cushion size and relief, carrying out test with sterile air introduced under conjunctiva in operation zone in combination with glycocorticosteroid preparation. Filtration cushion height increasing and air entering the anterior chamber, diuretic drugs are prescribed and preparations inhibiting intraocular fluid secretion. Filtration cushion becoming flat, glycocorticosteroid preparations, enzyme preparations are introduced and antimetabolite is introduced under conjunctiva outside of operation field. Filtration cushion relief being variable and air passes into the anterior chamber, anti-inflammatory therapy, anti-proliferative treatment course, glycocorticosteroid and enzyme preparations are prescribed. Filtration cushion becoming flat, and air does not enter the anterior chamber, gonioscopy is carried out and surgical intervention zones are revised in the cases of open internal fistula and antibiotic of cytostatic activity is to be prescribed. Internal fistula being blocked, laser surgical intervention is carried out. Hypertension being persistent, anti-glaucoma intervention is carried out in another eyeball segment with antibiotic of cytostatic activity being applied.
EFFECT: enhanced effectiveness of treatment selection.
FIELD: organic chemistry, medicine, ophthalmology, pharmacy.
SUBSTANCE: invention relates to novel derivatives of benzo[g]quinoline of the formula (I): as a free base or acid-additive salt used in treatment of glaucoma and myopia, and to a method for their synthesis and a pharmaceutical composition. In compound of the formula (I) each A and B means hydrogen atom (H); X means -CH2; Y means sulfur atom (S); R1 means H or (C1-C4)-alkyl wherein this compound can be in form of a free base or acid-additive salt. Method for synthesis of compound of the formula (I) by claim 1 or its salt involves the conversion step of alkoxy-group in compound of the formula (II): wherein A, B, X, Y and R1 have values given in claim 1; R3 means (C1-C4)-alkyl to hydroxy-group, and conversion of synthesized compounds of the formula (I) to free base or its acid-additive salt.
EFFECT: improved method of synthesis, valuable medicinal properties of compounds and pharmaceutical composition.
7 cl, 1 ex
FIELD: medicine, ophthalmology.
SUBSTANCE: method involves administration of chitosan sponge with square up to 2 cm2 into sub-Tenon's space wherein chitosan sponge shows the deacetylation degree 98%, its molecular mass is 1000 kDa and it comprises 2.8 x 10-9 g of hyaluronic acid, 27.8 x 10-8 g of chondroitinsulfuric acid, 3.06 x 10-11 g of cattle serum growth factor and 7 x 10-9 g of heparin per 1 mm2 of chitosan sponge. Method provides stabilizing visual function, to improving vision and expanding vision field based on enhancing sensitivity of optic nerve as result of blood stream enhancing. Invention can be used in treatment of progressing glaucoma with non-stabilizing functions.
EFFECT: improved method of treatment.
1 tbl, 1 ex
FIELD: medicine, ophthalmology, medicinal biochemistry.
SUBSTANCE: invention relates to manufacturing ophthalmic composition used for reducing intraocular pressure. Invention proposes using inhibitors of glycogen synthase kinase-3. Proposed composition provides reducing intraocular pressure by increasing intraocular liquid efflux and to prevent loss of retina ganglion cells.
EFFECT: valuable medicinal properties of inhibitors.
19 cl, 6 ex
SUBSTANCE: method involves introducing Mytomycin C metabolite into eyes where compensated and subcompensated intraocular pressure being achieved as a result of maximum hypotensive therapy application. The preparation is introduced 4 weeks in advance before operation in initial and advanced glaucoma stages and 2-3 weeks in advance in cases gone too far. The dose to be introduced is equal to 0.1 ml with concentration equal to 0.15 mg/ml. Additional Mytomycin C injection of the same volume and concentration of 0.2 mg/ml is introduced after having finished the reparative operation.
EFFECT: enhanced effectiveness of treatment; prolonged intraocular pressure stabilization.
FIELD: medicine, ophthalmology.
SUBSTANCE: method involves administration of the preparation "Ginkor-Fort" in the dose 1 tablet, 2 times per a day for 2 weeks and after one month break the preparation "Diovenor" is administrated in the dose 1 tablet, once per a day for 2 weeks at the constant instillation of the preparation "Ksalatan" in the dose 1 drop, once time before night. Such schedule of the method provides the stable normalization of intraocular pressure based on improvement of venous orbital and cerebral circulation. Invention is designated for medicinal treatment of glaucoma discirculatory variant.
EFFECT: improved method of treatment.
2 tbl, 1 ex
FIELD: medicine, ophthalmology.
SUBSTANCE: the present innovation deals with medicinal treatment of ischemic variant of primary glaucoma in case of stable normalization of intraocular pressure (IOP) in patients with myopic refraction. For this purpose, it is necessary to carry out electromagnetic impact successively onto cerebral orbital, temporal and occipital areas, carotid sinuses of cervical autonomic plexus, and, also, one should additionally inject gliatilin per 1.0 in combination with instillations of 0.5%-betaxolol solution per 2 drops twice daily into ocular conjunctival cavity. Therapy should last for 10 d at repeating the course once or twice annually. The method provides stable normalization of IOP, improves cerebral and orbital hemodynamics and stabilization of visual functions.
EFFECT: higher efficiency of therapy.
1 ex, 5 tbl
SUBSTANCE: invention concerns genetic engineering, biotechnology, immunology and medicine and can be applied in obtaining antitumoral vaccine and melanoma treatment. Vaccine compositions are based on heat shock proteins and antigen peptides for treatment of tumor disease, the said compositions containing hybrid protein consisting of heat shock HSP70 family protein and one of specific melanoma MAGE peptides (A1, A2, A3) or gp 100, as well as suitable pharmaceutical carrier. The invention also claims a method for obtaining the said hybrid proteins by gene expression in synthetic recombinant vectors in producer strains of E coli BL21 (DE3) cells.
EFFECT: improved immunising power.
3 cl, 4 ex, 1 tbl, 2 dwg
SUBSTANCE: invention reveals how to procure polypeptide forms in a solid state, in which the polypeptide is stabilised against degradation under physiological conditions or conditions that go beyond the limits for a long period of time. Stabilised polypeptide particles, which contain a polypeptide chosen from a super family polypeptide, which activates adenylate cyclase of the hypophysis/glucagons, and a stabilising agent chosen from disaccharides and monosaccharides, which are stable at a chosen acidic pH value, in this case the particles are made from a water solution, which has a chosen acidic pH value and are stable at temperatures till 60°C for a period of at least two months. The solid polypeptide particles under this particular invention provide stabilisation of the polypeptide, allowing them to achieve 96% restoration of the stabilised polypeptide after storage.
EFFECT: development of an effective way of getting stabilised polypeptide form in a solid state.
11 cl, 7 ex, 9 dwg, 8 tbl
SUBSTANCE: invention refers to medicine, specifically to phthisiology, and can be used for pulmonary tuberculosis treatment. For this purpose antibacterial treatment according is applied according to standard modes. In addition 5% unithiol solution in amount 5 ml per 200 ml of 0.9% sodium chloride solution is introduced intravenously. Unithiol introduction is alternated to contrical in amount 10 th.unit per 200 ml of 0.9% sodium chloride solution is introduced intravenously for the next day. Treatment course is 10 injections of each preparation. Invention widens range of pulmonary tuberculosis treatment, improving treatment efficiency due to reduction of abacillation time and degradation cavity closure, prevention of by-effects reactions of antitubercular preparations, removal of tubercular intoxication symptoms.
EFFECT: development of effective method of pulmonary tuberculosis treatment.
3 tbl, 2 ex
SUBSTANCE: substance of invention includes application of ligand associated with carrier, where ligand is protein FasL, or Fas leukocyte receptor-directed antibody, to reduce leukocyte activity for extracorporal application. Besides, this invention provides method of leukocyte activity reduction my means of specified module.
EFFECT: damaging action of associated activated leukocytes is inhibited by inactivation module within minutes.
9 cl, 1 ex, 1 tbl, 1 dwg
SUBSTANCE: invention concerns process of obtaining hydroxyl starch derivative which includes interaction of the reducing end of hydroxyalkyl starch represented by the formula (I), left unoxidised before this reaction, with a compound of formula (II) R'-NH-R", where R1 R2 and R3 independently denote hydrogen or linear or branched hydroxyalkyl group while R' or R" or R' and R" include at least one functional group X capable of interaction with at least one more compound before or after the reaction of (I) and (II). The invention also concerns hydroxyl starch derivative obtained in this process, and production process for hydroxyl starch derivative and polypeptide, a pharmaceutical composition incorporating the said hydroxyl starch derivatives.
EFFECT: improvement of compound production.
77 cl, 21 dwg, 3 tbl
FIELD: medicine; ophthalmology.
SUBSTANCE: for this purpose total area of avascular retina is applied with coagulates anteriad of axis. Then transpupillary laser coagulation of avascular areas is carried out. Laser coagulation is followed with course of parabulbar injections of 1% retinalamin solution dosed 0.4-0.5 ml once a day during 10 days. Besides over a period of treatment daily instillation of steroid, antioxidants and non-steroid anti-inflammatory agents is performed under forced regimen - 6 times per hour with interval 10 minutes.
EFFECT: enables to block retina avascular areas, to stop transsudate disease component, and to improve avascular areas blood supply.
FIELD: genetic engineering.
SUBSTANCE: invention refers to polypeptides GPCR Drosophila melanogaster (DmGPCR) and polynucleotides detecting and coding such polypeptides. Construction of expressing vectors based on specified polynucleotides and production of containing host cells enables to apply DmGPCR as insecticides. Besides, invention refers to methods of DmGPCR-bindnig, method of DmGPCR expression and activity modulator identification, method of insect population control using DmGPCR-antibody, DmGPCR antisense polynucleotides, DmGPCR binding partner or modulator.
EFFECT: new application of polypeptides.
35 cl, 7 tbl, 10 ex
FIELD: technological processes.
SUBSTANCE: protein variants are suggested that possess lysozyme activity. Protein-based antibacterial substance is described. DNA molecule is discovered that codes the specified protein, and also procariotic cell is discovered that contained the specified DNA molecule. Method is described to prepare protein with the help of procariotic cell.
EFFECT: simplifies preparation of antibacterial substance in commercially significant volumes.
13 cl, 3 ex
FIELD: medicine; chemistry-pharmaceutical industry.
SUBSTANCE: trophoblastic beta-1-glycoprotein is released from serosity produced as a result of differential centrifugation of retroplacental human blood. Supernatant after first centrifugation is saturated with sodium chloride (0.1-1.0 mole/l) to prevent non-specific sorption and centrifuged once more with triton X-100 (0.01-0.05%) to virus inactivation. Then it is applied to affine sorbent that is sepharose with solid-phase monoclonal antibodies to trophoblastic beta-1-glycoprotein. Protein is eluated with 0.1 M glycine-HCI buffer solution, and after neutralization and in-depth analysis second affine chromatography is carried out on sepharose with modified protein G, released from streptococcus cell wall to prevent immunoglobulin contamination. Solution passed through column and trophoblastic beta-1-glycoprotein is been concentrating and dialyzing from saline and lyophilized.
EFFECT: increased output and purity of end product.
FIELD: technological processes.
SUBSTANCE: this invention is related to biotechnology, to be more precise, to preparation of proteins out of milk, and may be used for prevention or treatment disorders related to metabolism in bones and immune function. Osteoprotegrin is prepared out of human or cow milk and has glycolysis profile that produces polypeptide with molecular mass of approximately 80, 130 and 200 kilodaltons. Prepared protein is used in structure of food substance and pharmaceutical composition for prevention or treatment of disorders related with bone remodeling, and/or immune disorders. Also prepared protein is added to make fodder.
EFFECT: invention allows simple and efficient preparation of stable biologically active form of protein osteoprotegrin out of natural sources.
20 cl, 7 dwg, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention concerns chemical pharmaceutical industry, particularly a medicine for treatment of viral disease, including HIV infection (AIDS and HIV related diseases). The antiviral medicine is a solution containing fullerene-polyhydropolyaminocaproic acid and dimethyl sulfoxide in the following component content per ampoule: fullerene-polyhydropolyaminocaproic acid 50 mg, dimethyl sulfoxide up to 0.5 ml. The medicine is intended for intramuscular or intravenous (drip-feed) administration, and dissolved in 20 ml of water for intramuscular administration, while the variant for intravenous administration includes additionally 20 ml of 0.9% sodium chloride solution per 1 ampoule.
EFFECT: obtaining antiviral medicine for treatment of virus diseases including HIV infection.